Neurogene’s stock sinks after adverse event with Rett syndrome gene therapy

Neurogene’s stock has dropped by nearly 35% in pre-market trading after a patient in its Rett syndrome gene therapy trial suffered a serious adverse event (AE).

The clinical-stage company announced that the third patient in the high-dose cohort suffered a serious AE associated with known risks of AAV gene therapy in the Phase I/II Rett disease trial (NCT05898620).